Use of nutritional compositions with phospholipid sphingolipid and cholesterol

Abstract

A nutritional composition comprising phospholipids, sphingolipids and cholesterol for the prevention of obesity and/or diabetes is provided.

1 . Use of a composition comprising a lipid, protein and digestible carbohydrate component and:
 (a) 0.5 to 20 wt. % phospholipids based on total lipid;   (b) 0.1 to 20 wt. % sphingolipids based on total lipid; and   (c) 0.005 to 10 wt. % cholesterol based on total lipid,   
       for the manufacture of a nutritional composition to be administered to a non-obese infant with the age below 36 months for the prevention of obesity and/or diabetes type 2. 
     
     
         2 . Use according to  claim 1  wherein the composition further comprises at least 0.5 wt. % of at least one soluble, non-digestible oligosaccharides based on dry weight of the composition. 
     
     
         3 . Use according to any of the preceding claims, wherein the lipid component comprises (a) linoleic acid (LA) and alpha-linolenic acid (ALA) in a weight ratio of LA/ALA between 2 and 7;
 (b) less than 15 wt. % LA based on total fatty acids; and   (c) at least 1 wt. % ALA based on total fatty acids,   
     
     
         5 . Use according to any of the preceding claims wherein the lipid component provides 35 to 55% of the total calories, the protein component provides 5 to 15% of the total calories and the digestible carbohydrate component provides 30 to 60% of the total calories. 
     
     
         6 . Use according to any of the preceding claims for preventing the development of obesity later-in-life and/or for preventing the development of obesity when said infant has an age above 36 months. 
     
     
         7 . Use according to any one of the preceding claims, wherein the nutritional composition is administered to an infant with the age below 12 months. 
     
     
         8 . Use according to any of the preceding claims wherein the composition comprises at least one soluble, non-digestible oligosaccharides selected from the group consisting of fructo-oligosaccharides (including inulin), galacto-oligosaccharides (including transgalacto-oligosaccharides), gluco-oligosaccharides (including gentio-, nigero- and cyclodextrin-oligosaccharides), arabino-oligosaccharides, mannan-oligosaccharides, xylo-oligosaccharides, fuco-oligosaccharides, arabinogalacto-oligosaccharides, glucomanno-oligosaccharides, galactomanno-oligosaccharides, sialic acid comprising oligosaccharides and uronic acid oligosaccharides. 
     
     
         9 . Use according to claim any of the preceding claims wherein the composition comprises galacto-oligosaccharides. 
     
     
         10 . Use of a composition described in any one of the preceding claims for the manufacture of a nutritional composition to be administered to an infant with the age below 36 months for the preventing the development of a disorder when said human has an age above 36 months, wherein said disorder is selected from the group consisting of type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea. 
     
     
         11 . Use of a composition according to any of the preceding claims for the manufacture of a nutritional composition for the prevention and/or treatment of type 2 diabetes and/or for the dietary management of type 2 diabetes.